Pooled Analysis of Cardiovascular Safety With Fremanezumab Treatment in Patients With Migraine by Number of Cardiovascular or Cerebrovascular Risk Factors

被引：0
|
作者：
Juergens, T. P. [1 ]
Ning, X. [2 ]
Kessler, Y. [2 ]
Cohen, J. M. [3 ]
Yang, R. [2 ]
Diener, H. [4 ]
机构：
[1] Univ Med Ctr Rostock, Headache Ctr North East, Dept Neurol, Rostock, Mecklenburg Vor, Germany
[2] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[3] Teva Branded Pharmaceut Prod R&D Inc, Frazer, PA USA
[4] Univ Duisburg Essen, Essen, Nordrhein Westf, Germany
来源：
HEADACHE | 2020年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [21] Safety and Tolerability of Fremanezumab in Patients With Episodic and Chronic Migraine: a Pooled Analysis of Phase 3 Studies
    Vargas, Bert B.
    Ning, Xiaoping
    Kessler, Yoel
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    McAllister, Peter
    NEUROLOGY, 2020, 94 (15)
  • [22] Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
    Diener, Hans Christoph
    McAllister, Peter
    Jurgens, Tim P.
    Kessler, Yoel
    Ning, Xiaoping
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Barash, Steve
    Silberstein, Stephen D.
    CEPHALALGIA, 2022, 42 (08) : 769 - 780
  • [23] Safety and Tolerability of Fremanezumab in Patients with Episodic and Chronic Migraine: A Pooled Analysis of Phase 3 Studies
    McAllister, Peter
    Ning, Xiaoping
    Kessler, Yoel
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    ANNALS OF NEUROLOGY, 2020, 88 : S158 - S159
  • [24] Erenumab Safety Among Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors
    Winner, Paul
    Reuter, Uwe
    Dodick, David
    Kudrow, David
    Rozniecki, Jacek
    Xue, Fei
    Zhang, Feng
    Cheng, Sunfa
    Picard, Hernan
    Mikol, Daniel
    NEUROLOGY, 2018, 90
  • [25] Migraine linked to cardiovascular risk factors
    不详
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2005, 12 (02): : 189 - 189
  • [26] Cardiovascular risk factors associated with migraine
    Silberstein, SD
    LANCET NEUROLOGY, 2005, 4 (07): : 391 - 392
  • [27] Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data
    Davies, Michael J.
    Merton, Katherine
    Vijapurkar, Ujjwala
    Yee, Jacqueline
    Qiu, Rong
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [28] Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data
    Michael J. Davies
    Katherine Merton
    Ujjwala Vijapurkar
    Jacqueline Yee
    Rong Qiu
    Cardiovascular Diabetology, 16
  • [29] Prevention of cardiovascular risk factors for patients that have endured cerebrovascular event
    Salazar Olaya, Giancarlo
    Gafas Gonzalez, Carlos
    Figueredo Villa, Katiuska
    Solis Cartas, Urbano
    REVISTA CUBANA DE REUMATOLOGIA, 2021, 23 (02):
  • [30] Safety and Efficacy of Fremanezumab in Different Racial and Ethnic Subgroups of Patients with Migraine: A Pooled Analysis of Phase 3 Studies
    Charleston, Larry
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Barash, Steve
    Lengil, Tamar
    Ojwang, Beryl
    Kim, Byung-Kun
    ANNALS OF NEUROLOGY, 2022, 92 : S42 - S43
12345